Seattle Genetics

seattlegenetics.com

Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

US FDA APPROVE SEATTLE GENETICS' ADCETRIS FOR PCALCL AND CD30-EXPRESSING MYCOSIS FUNGOIDES

pharmabiz | November 11, 2017

news image

Seattle Genetics has announced that the US Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy. Primary cutaneous ALCL and MF are the most common subtypes of cutaneous T-cell lymphoma (CTCL)....

Read More

GERMAN CHEMICALS GROUP ATOTECH FILES FOR AN ESTIMATED $1 BILLION US IPO

Nasdaq | January 15, 2020

news image

Atotech, a Carlyle-backed specialty chemicals company carved out of Total, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.However, the deal size is likely a placeholder for an IPO that we estimate could raise $1 billion. The Berlin, Germany-based company was founded in 1993 and booked $1.2 billion in revenue for the 12 months ended September 30, 2019. It plans to list on the NYSE under the symbol ATC. Atotech filed confidentially on June 7, 2019. ...

Read More

SASOL CONFIRMS INCIDENT AT LAKE CHARLES CHEMICALS PROJECT (LCCP) LOW-DENSITY POLYETHYLENE UNIT

PR Newswire | January 14, 2020

news image

The new LDPE unit had not yet achieved beneficial operation (BO) as planned for in December 2019. The unit was in the final stages of commissioning and startup when the incident occurred. The unit has been shut down and an investigation is underway to determine the cause of the incident, the extent of the damage and resulting impact on the LDPE unit's BO schedule. All other Lake Charles units and previously commissioned LCCP units, namely the ethane cracker, ethylene glycol/ethylene oxide an...

Read More

LANXESS COMPLETES SALE OF CHROME CHEMICAL BUSINESS

Chemical Technology | January 13, 2020

news image

German specialty chemicals company Lanxess has completed the sale of its chrome chemicals business to Chinese leather chemicals producer Brother Enterprises for €80m ($89m). The deal was first announced on 12 August last year, when the two companies signed an agreement. Lanxess noted that the transaction obtained all the necessary approvals from the relevant antitrust authorities. A part of Lanxess Leather business unit, the chrome chemicals business has been generating an annual revenue of...

Read More
news image

US FDA APPROVE SEATTLE GENETICS' ADCETRIS FOR PCALCL AND CD30-EXPRESSING MYCOSIS FUNGOIDES

pharmabiz | November 11, 2017

Seattle Genetics has announced that the US Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy. Primary cutaneous ALCL and MF are the most common subtypes of cutaneous T-cell lymphoma (CTCL)....

Read More
news image

GERMAN CHEMICALS GROUP ATOTECH FILES FOR AN ESTIMATED $1 BILLION US IPO

Nasdaq | January 15, 2020

Atotech, a Carlyle-backed specialty chemicals company carved out of Total, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.However, the deal size is likely a placeholder for an IPO that we estimate could raise $1 billion. The Berlin, Germany-based company was founded in 1993 and booked $1.2 billion in revenue for the 12 months ended September 30, 2019. It plans to list on the NYSE under the symbol ATC. Atotech filed confidentially on June 7, 2019. ...

Read More
news image

SASOL CONFIRMS INCIDENT AT LAKE CHARLES CHEMICALS PROJECT (LCCP) LOW-DENSITY POLYETHYLENE UNIT

PR Newswire | January 14, 2020

The new LDPE unit had not yet achieved beneficial operation (BO) as planned for in December 2019. The unit was in the final stages of commissioning and startup when the incident occurred. The unit has been shut down and an investigation is underway to determine the cause of the incident, the extent of the damage and resulting impact on the LDPE unit's BO schedule. All other Lake Charles units and previously commissioned LCCP units, namely the ethane cracker, ethylene glycol/ethylene oxide an...

Read More
news image

LANXESS COMPLETES SALE OF CHROME CHEMICAL BUSINESS

Chemical Technology | January 13, 2020

German specialty chemicals company Lanxess has completed the sale of its chrome chemicals business to Chinese leather chemicals producer Brother Enterprises for €80m ($89m). The deal was first announced on 12 August last year, when the two companies signed an agreement. Lanxess noted that the transaction obtained all the necessary approvals from the relevant antitrust authorities. A part of Lanxess Leather business unit, the chrome chemicals business has been generating an annual revenue of...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us